SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2012 Payment	Dec. 31, 2014 Quarter Payment Customer	Dec. 31, 2013 Customer	Dec. 31, 2012
Cash, Cash Equivalents and Investments [Abstract]
Aggregate fair value of investments		$ 12,200,000	$ 7,000,000
Held-to-maturity securities, unrecognized gain		0	0	0
Held-to-maturity securities, unrecognized loss		0	0	0
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current		10,900,437	6,966,964
Held-to-maturity securities, noncurrent		1,250,000	0
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable		2,987,047	5,004,418
Number of customers		1	2
Royalty revenue		12,985,370	11,767,758	9,155,654
Deferred revenue recognized		59,255	133,524	372,705
Outstanding deferred revenue amount		148,135	207,390
Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]
Number of quarters after which revenue is recognized		1
Number of days after calendar year, after which payments and report are received		90 days
Treasury Stock [Abstract]
Treasury stock purchased (in shares)		30,848	40,107	66,028
Average price of share (in dollars per share)		$ 26.89	$ 16.83	$ 15.67
Reimbursable Third Party Development Costs [Abstract]
Accrued patent costs		34,000	60,000
Royalty Buy-Down [Abstract]
Royalty expenses		800,000	400,000	300,000
Initial payment for royalty buy down	1,500,000	60,000
Number of additional cash payments for royalty buy-down	5
Number of cash payments made for royalty obligation		2
Amount amortized related to agreement		109,000	0	0
Deferred royalty buy-down - long term		3,800,000
Deferred costs, amortization period		5 years
Net Patent Costs [Abstract]
Net patent costs		295,030	215,999
Estimated aggregate amortization expense [Abstract]
2015		43,000
2016		35,000
2017		35,000
2018		35,000
2019		35,000
Patents [Member]
Net Patent Costs [Abstract]
Patents		671,326	472,375
Accumulated Amortization		(376,296)	(256,376)
Net patent costs		295,030	215,999
Increase in capitalized patent costs		199,000
Capitalized patents costs reimbursable to customer		34,000
Amortization expense for patents		119,920	64,323	64,190
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets with definite lives useful life (in years)		1 year
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets with definite lives useful life (in years)		13 years
DFB Biotech Inc. [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable			3,500,000
DFB Biotech Inc. [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)			70.00%
Auxilium [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable		2,900,000	1,500,000
Royalty revenue		14,000,000	10,900,000	8,200,000
Auxilium [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)			30.00%
Pre-refunded Municipal Bonds [Member]
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current		2,287,773	0
Held-to-maturity securities, noncurrent		0	0
Certificates of Deposit [Member]
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity securities, current		8,612,664	6,966,964
Held-to-maturity securities, noncurrent		$ 1,250,000	$ 0